[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Lada PE, Taborda B, Sánchez M, Tommasino J, Rosso FF, Gramática L, Alecha Gil J, Echenique Elizondo M: [Adenosquamous and squamous carcinoma of the gallbladder]. Cir Esp; 2007 Apr;81(4):202-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous and squamous carcinoma of the gallbladder].
  • [Transliterated title] Carcinoma adenoescamoso y epidermoide de la vesícula biliar.
  • INTRODUCTION: Squamous and adenosquamous carcinomas of the gallbladder have poor prognosis.
  • Because these tumors are silent in the initial stage, they are generally diagnosed in advanced stages.
  • MATERIAL AND METHOD: We performed a retrospective observational study of five patients with squamous or adenosquamous carcinoma of the gallbladder.
  • Pathologic analysis revealed epidermoid carcinoma in two patients and adenosquamous carcinoma in three patients.
  • Two patients were treated with adjuvant chemotherapy.
  • CONCLUSIONS: In both histological types of gallbladder carcinoma, treatment depends on the grade of local and regional invasion and tumor spread at diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403356.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Julka PK, Puri T, Rath GK: A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2006 Feb;5(1):110-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
  • BACKGROUND: Patients with carcinoma of the gallbladder have advanced, unresectable tumor at the time of presentation and face a dismal prognosis in the absence of a standard palliative chemotherapy regimen.
  • This study was undertaken to evaluate the efficacy and safety of combined chemotherapy of gemcitabine and carboplatin in 20 patients with advanced gallbladder carcinoma.
  • METHODS: The criteria of eligibility included chemonaive patients with unresectable gallbladder cancer, bidimensionally measurable disease, Zubrod's performance status < or = 2, and adequate major organ function.
  • RESULTS: In this group of 20 patients with advanced gallbladder carcinoma 6 were men and 14 women, with a median age of 55 years.
  • The stage of the tumor at presentation was IVB in 14 patients (70%), IVA in 3 (15%) and III in 3 (15%).
  • The median time to progression of the tumor was 33.8 weeks, and 1-year survival rate of the patients was 43.3%.
  • CONCLUSION: With mild toxicity, combined chemotherapy of gemcitabine and carboplatin is effective in the treatment of advanced gallbladder carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481295.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Liu KH, Yeh TS, Hwang TL, Jan YY, Chen MF: Surgical management of gallbladder sarcomatoid carcinoma. World J Gastroenterol; 2009 Apr 21;15(15):1876-9
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of gallbladder sarcomatoid carcinoma.
  • AIM: To study the behavior as well as optimal treatment of gallbladder sarcomatoid carcinoma, we reviewed the results of treatment of gallbladder sarcomatoid carcinoma from Chang Gung Memorial Hospital.
  • METHODS: From 1987 to 2005, six patients were diagnosed with gallbladder sarcomatoid carcinoma and treated at our institution.
  • Tumor staging was based on 2002 revised tumor-node-metastasis (TNM) staging for gall bladder cancer from the American Joint Committee on Cancer.
  • The follow-up time ranged from 30 d to 5 mo.
  • The prognosis was extremely poor, even after curative resection and postoperative chemotherapy.
  • CONCLUSION: The prognosis of gallbladder sarcomatoid carcinoma was not dependent on TNM stage and was always dismal.
  • The clinicopathological features were different from those of gall bladder cancer.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kurume Med J. 1999;46(3-4):175-9 [10659595.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):818-21 [15985237.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):557-69 [10998654.001]
  • [Cites] Surg Today. 2002;32(5):462-7 [12061703.001]
  • [Cites] J Gastroenterol. 2002;37(11):966-71 [12483254.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):e406-8 [14521442.001]
  • [Cites] J Pathol. 1971 Jun;104(2):145-8 [5286390.001]
  • [Cites] Cancer. 1984 May 15;53(10):2171-7 [6704904.001]
  • [Cites] Acta Pathol Jpn. 1986 Jun;36(6):913-20 [3766137.001]
  • [Cites] Am Surg. 1988 Aug;54(8):492-4 [3395026.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):992-7 [2386928.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):176-87 [8367625.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):314-6 [8071517.001]
  • [Cites] J Surg Oncol. 1996 Jan;61(1):49-55 [8544460.001]
  • [Cites] AJR Am J Roentgenol. 1996 May;166(5):1233-4 [8615287.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):866-71 [15533231.001]
  • [Cites] World J Surg. 2005 Jan;29(1):72-5 [15599737.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Jun;17(6):683-5 [15879734.001]
  • [Cites] Pathology. 2000 Feb;32(1):41, 63-4 [10740804.001]
  • (PMID = 19370786.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2670416
  •  go-up   go-down


Advertisement
4. Pavithran K, Prabhash K, Hazarika D, Doval DC: Neuroendocrine carcinoma of gallbladder: report of 2 cases. Hepatobiliary Pancreat Dis Int; 2005 Feb;4(1):144-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinoma of gallbladder: report of 2 cases.
  • BACKGROUND: Neuroendocrine carcinoma of the gallbladder is rare.
  • Its best treatment is not known.
  • The two patients underwent revision surgery followed by chemotherapy.
  • RESULTS: Both patients tolerated the second stage surgery well, which was followed by chemotherapy with paclitaxel, ifosphamide and cisplatin for 6 cycles.
  • They were treated this way for 8 months and 12 months post treatment, respectively.
  • CONCLUSIONS: A proper diagnosis of neuroendocrine carcinoma is made often after surgery.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Cholecystectomy / methods. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730940.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D: Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys; 2002 Jan 1;52(1):167-75
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.
  • PURPOSE: This study was performed to evaluate the outcome of patients with gallbladder cancer who received postoperative concurrent chemotherapy and radiation therapy.
  • METHODS AND MATERIALS: Curative resection followed by adjuvant combined modality therapy with external beam radiation therapy (EBRT) and chemotherapy was attempted in 21 consecutive gallbladder carcinoma (GBC) patients at the Mayo Clinic from 1985 through 1997.
  • EBRT fields encompassed the tumor bed and regional lymph nodes (median dose of 54 Gy in 1.8-2.0-Gy fractions).
  • One patient received 15 Gy intraoperatively after EBRT.
  • One patient had Stage I disease, and 20 had Stage III-IV disease.
  • The 5-year survival rate of patients with Stage I-III disease was 65% vs. 0% for those with Stage IV disease (p < 0.02).
  • Five-year local control rates were 100% for the 6 patients who received total EBRT doses >54 Gy (microscopic residual, 3 patients; gross residual, 1 patient; negative but narrow margins, 2 patients) vs. 65% for the 15 who received a lower dose (3, gross residual; 2, microresidual; 10, negative margins).
  • CONCLUSION: Patients with completely resected (negative margins) GBC followed by adjuvant EBRT plus 5-fluorouracil chemotherapy had a relatively favorable prognosis, with a 5-year survival rate of 64%.
  • Both tumor stage and extent of resection seemed to influence survival and local control.
  • More aggressive measures using current cancer therapies and integration of new cancer treatment modalities will be required to favorably impact on the poor prognosis of patients with Stage IV or subtotally resected GBC.
  • [MeSH-major] Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11777635.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Daines WP, Rajagopalan V, Grossbard ML, Kozuch P: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2. Oncology (Williston Park); 2004 Jul;18(8):1049-59; discussion 1060, 1065-6, 1068
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2.
  • Gallbladder carcinoma and carcinoma of the bile ducts are relatively rare cancers in the United States.
  • These cancers are often diagnosed in an advanced stage due to their nonspecific symptomatology and until recently have been associated with a dismal prognosis.
  • Recent advances in imaging and surgical techniques along with emerging options in palliative chemotherapy have improved the outlook in these cancers.
  • While complete surgical resection remains the only hope of cure in both these cancers, palliative biliary decompression and chemotherapy result in substantial improvement in quality of life.
  • In part 2, we examine palliative care and systemic therapy in gallbladder and biliary tract carcinomas, as well as the use of liver transplantation in the treatment of cholangiocarcinomas.
  • [MeSH-major] Biliary Tract Neoplasms / surgery. Gallbladder Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma. Chemotherapy, Adjuvant. Cholangiocarcinoma / therapy. Combined Modality Therapy. Decompression, Surgical. Humans. Liver Transplantation. Palliative Care. Prognosis. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15328897.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


7. Abahssain H, Afchain P, Melas N, Ismaili N, Rahali R, Rabti HM, Errihani H: [Chemotherapy in gallbladder carcinoma]. Presse Med; 2010 Dec;39(12):1238-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy in gallbladder carcinoma].
  • [Transliterated title] Chimiothérapie dans le cancer de la vésicule biliaire.
  • Gallbladder cancer is an aggressive tumor.
  • Surgery is the standard treatment for localized stage but there is no standard treatment in metastatic or locally advanced disease.
  • Because of the rarity of bile tract cancer (BTC) and gallblader carcinoma (GBC), most studies have grouped all BTC and GBC together, and there are very few GBC-specific studies.
  • Adjuvant therapy after surgical resection is not validated.
  • Understanding the molecular mechanisms of carcinogenesis of GBC has opened the way for the use of targeted therapies.
  • This new treatment would improve survival and quality of life of our patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Capecitabine. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Invasiveness. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21074352.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Rajagopalan V, Daines WP, Grossbard ML, Kozuch P: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Williston Park); 2004 Jun;18(7):889-96
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1.
  • Gallbladder carcinoma and carcinoma of the bile ducts are relatively rare cancers in the United States.
  • These cancers are often diagnosed in an advanced stage due to their nonspecific symptomatology and until recently have been associated with a dismal prognosis.
  • Recent advances in imaging and surgical techniques along with emerging options in palliative chemotherapy have improved the outlook in these cancers.
  • While complete surgical resection remains the only hope of cure in both these cancers, palliative biliary decompression and chemotherapy result in substantial improvement in quality of life.
  • In part 2, which will appear next month, we will review palliative care and systemic therapy in gallbladder and biliary tract carcinomas, as well as the use of liver transplantation in the treatment of cholangiocarcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Biliary Tract Neoplasms / surgery. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15255172.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


9. Park JS, Yoon DS, Kim KS, Choi JS, Lee WJ, Chi HS, Kim BR: Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma. J Gastrointest Surg; 2007 May;11(5):631-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma.
  • Despite the advances in imaging techniques, most patients can only be diagnosed at advanced stage: The prognosis is very poor.
  • Recent studies showed that aggressive radical resection for advanced gallbladder carcinoma can give an acceptable prognosis.
  • However, recurrence frequently remains the main problem after curative resection of advanced gallbladder carcinoma.
  • The aim of this study was to identify the patterns and risk factors of recurrence after curative resection for stage II gallbladder carcinoma.
  • Between January 1991 and December 2003, 100 patients received radical curative resection for gallbladder carcinoma at Yonsei University Medical Center.
  • Of these, 77 were defined with stage II gallbladder carcinoma according to the Union Internationale Contre Le Cancer classification (sixth edition).
  • Infiltrating and poorly differentiated types were identified as independent prognostic factors of recurrence after curative resection for stage II gallbladder carcinoma and it suggests that large multicenter randomized control trials are necessary to clarify the role of adjuvant chemotherapy in these patients.
  • [MeSH-major] Carcinoma / surgery. Gallbladder Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Cholecystectomy / classification. Cholecystectomy, Laparoscopic. Colectomy. Common Bile Duct / surgery. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Seeding. Neoplasm Staging. Pancreaticoduodenectomy. Retrospective Studies. Risk Factors. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1996 Nov;224(5):639-46 [8916879.001]
  • [Cites] Surg Endosc. 2000 Aug;14(8):712-6 [10954815.001]
  • [Cites] Curr Probl Surg. 1995 Jan;32(1):1-90 [7528652.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] World J Surg. 1999 Oct;23(10):989-95; discussion 996-7 [10512937.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1609-11 [15532788.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):200-4 [9052434.001]
  • [Cites] Surgery. 1996 Nov;120(5):816-21 [8909516.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):83-9; discussion 89 [14746839.001]
  • [Cites] J Am Coll Surg. 2001 May;192(5):600-7 [11333097.001]
  • [Cites] Ann Surg. 1992 Nov;216(5):565-8 [1359844.001]
  • [Cites] Am J Surg. 1992 Feb;163(2):239-45 [1739180.001]
  • (PMID = 17468922.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ishikawa T, Horimi T, Shima Y, Okabayashi T, Nishioka Y, Hamada M, Ichikawa J, Tsuji A, Takamatsu M, Morita S: Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder. J Hepatobiliary Pancreat Surg; 2003;10(3):233-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder.
  • BACKGROUND/PURPOSE: An aggressive approach is required to resect advanced carcinoma of the gallbladder.
  • Therefore, an extended surgical procedure often brings about a poor surgical outcome.
  • To test whether an aggressive surgical treatment can improve the survival rate for primary advanced carcinoma of the gallbladder, 59 patients with stage IV primary gallbladder carcinoma were studied.
  • METHODS: Patients were divided into three treatment groups for the survival analysis: group A (resectional surgery, n = 29), group B (low-dose cis-diamminedichloroplatinum-II and 5-fluorouracil therapy, n = 10), and group C (exploratory laparotomy, other treatment modalities, or no treatment, n = 20).
  • Also, there was no significant difference in the survival rate between the patients resected with distant metastasis (group A2) and chemotherapy cases (group B).
  • CONCLUSIONS: These results indicated that radical surgery should be performed for patients with no distant metastasis, and that chemotherapy might be a useful alternative treatment for patients with distant metastasis in advanced carcinoma of the gallbladder.
  • [MeSH-major] Adenocarcinoma / surgery. Gallbladder Neoplasms / surgery. Hepatectomy / methods. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cholecystectomy / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy / methods. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14605981.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Orth K, Beger HG: Gallbladder carcinoma and surgical treatment. Langenbecks Arch Surg; 2000 Dec;385(8):501-8
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder carcinoma and surgical treatment.
  • Gallbladder carcinoma shows an unusual geographic and demographic distribution.
  • The frequency of gallbladder cancer in all operations of the biliary tract is about 1-3%, reflecting the commonest biliary tract malignancy.
  • Preoperative imaging, including ultrasound and computed tomography (CT), may reveal signs indicative of the presence of malignancy.
  • Survival depends on the ability to achieve a curative resection, including hepatectomy and lymph node dissection in patients with local extended tumour according to the stage of the disease.
  • Overall, the curative resection rates for gallbladder carcinoma range from 10% to 30%.
  • For those patients with unresectable cancer, palliative surgical, endoscopic or radiological bypass procedures can improve quality of life.
  • Other approaches to the management of advanced tumours include systemic chemotherapy or combined chemo-radiotherapy and need further evaluation.
  • Early-stage tumours are often discovered as an incidental finding during (laparoscopic) cholecystectomy or on histological examination of the gallbladder, mostly necessitating relaparotomy and extensive resection.
  • In the following, management of patients with gallbladder cancer at different stages and situations is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11201005.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 76
  •  go-up   go-down


12. Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, Bhatia S, Nagorney DM: Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):150-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.
  • PURPOSE: To analyze the effect of adjuvant chemoradiotherapy on gallbladder carcinoma.
  • METHODS AND MATERIALS: We retrospectively reviewed the records from consecutive patients who underwent R0 resection of gallbladder carcinoma between January 1, 1985, and December 31, 2004.
  • Patients had either Stage I (T1-T2N0M0) or Stage II (T3N0M0 or T1-T3N1M0) disease.
  • Patients undergoing adjuvant therapy received 5-fluorouracil chemotherapy concurrently with radiotherapy (median dosage, 50.4 Gy in 28 fractions).
  • Adverse prognostic factors and the effect of adjuvant treatment on overall survival (OS) were evaluated.
  • On univariate analysis, no adverse prognostic factors for OS reached statistical significance, but trends were noted for Stage N1 vs. N0 (p = .06), Nx vs. N0 (p = .09), Stage T3 vs. T1-T2 (p = .06), and histologic findings other than adenocarcinoma (p = .13).
  • However, a significantly greater percentage of patients receiving adjuvant chemoradiotherapy had Stage II disease (p <.001).
  • CONCLUSION: After adjusting for the stage parameters and histologic findings, our data suggest that adjuvant chemoradiotherapy might improve OS for patients with gallbladder cancer.
  • [MeSH-major] Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiotherapy. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19297105.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Puhalla H, Bareck E, Scheithauer W, Ploner M, Stiglbauer W, Depisch D: [Therapy of gallbladder carcinoma. Experience of a central hospital]. Chirurg; 2002 Jan;73(1):50-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of gallbladder carcinoma. Experience of a central hospital].
  • [Transliterated title] Die Therapie des Gallenblasenkarzinoms. Eine Standortanalyse.
  • INTRODUCTION: There are various options for the treatment of gallbladder carcinoma; however, only radical resection offers a chance for prolonged survival.
  • METHODS: The aim of this study was to analyze retrospectively patients suffering from gallbladder carcinoma in a central hospital in Austria.
  • RESULTS: In 28 patients the cancer was resected and 22 persons underwent palliative surgery.
  • Eleven patients had no surgical therapy, 10 persons received gemcitabine or a combination chemotherapy regimen consisting of leucoverin, 5-fluorouracil and mitomycin C.
  • The median survival of patients without chemotherapy following radical resection (n = 15) was 10.7 months (one patient with metastatic cancer was excluded) and for patients with tumor remaining margins (n = 8) 3.2 months (P = 0.023).
  • Without chemotherapy the median patient survival following palliative resection (n = 17) and explorative laparotomy (n = 15) was 1.5 months and 2.1 months.
  • The median survival without surgical therapy was 1.6 months.
  • Chemotherapy was administered to four of the resected patients (median survival 16.5 months), in five patients following palliative surgery and in one patient after explorative laparotomy (median survival 4.3 months) (P = 0.034).
  • Following radical resection in an early tumor stage and combining this approach with an established chemotherapy, patient survival could be increased significantly.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cholecystectomy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / therapeutic use. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Palliative Care. Postoperative Care. Regression Analysis. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11974462.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Yanagawa T, Shimizu J, Dono K, Yasumoto T, Hata T, Fujino S, Kitahara T, Munakata K, Watanabe N, Takamoto K, Nagai K, Miyake M, Hata T, Kawanishi K, Ikeda K, Fujita J, Akagi K, Iwasawa T, Kitada M, Shimano T: [A case report--transarterial embolization for advanced gallbladder carcinoma with hepatic metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2711-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--transarterial embolization for advanced gallbladder carcinoma with hepatic metastasis].
  • CT revealed a primary gallbladder carcinoma Stage IVb with multiple hepatic metastases.
  • For her poor performance status, it seems to be too difficult to undergo a general chemotherapy.
  • She underwent 2 times TAE.
  • TAE may be useful for advanced gallbladder carcinoma with tumor vascularity.
  • [MeSH-major] Embolization, Therapeutic. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224688.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL: Trimodality therapy for advanced gallbladder cancer. Am Surg; 2001 Mar;67(3):277-83; discussion 284
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality therapy for advanced gallbladder cancer.
  • We conducted a retrospective review of all patients who underwent surgical extirpation for stage III, stage IV, or recurrent carcinoma of the gallbladder.
  • Between 1991 and 1999 ten patients underwent surgical resection for advanced gallbladder cancer.
  • All patients received adjuvant therapy either pre- or postoperatively.
  • Radiotherapy was used in all patients and chemotherapy in 90 per cent of patients.
  • An additional patient with stage II disease initially was also treated surgically for a local recurrence.
  • Surgical management involved cholecystectomy and resection of various amounts of liver surrounding the gallbladder bed and regional lymphadenectomy.
  • We conclude that trimodality therapy in selected patients with stage III, IV, or recurrent carcinoma of the gallbladder is possible and may result in prolonged survival.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Cholecystectomy. Gallbladder Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Acute Disease. Aged. Chemotherapy, Adjuvant. Cholecystitis / etiology. Chronic Disease. Female. Humans. Jaundice / etiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11270889.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Misra MC, Guleria S: Management of cancer gallbladder found as a surprise on a resected gallbladder specimen. J Surg Oncol; 2006 Jun 15;93(8):690-8
MedlinePlus Health Information. consumer health - Gallbladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cancer gallbladder found as a surprise on a resected gallbladder specimen.
  • Carcinoma gallbladder is associated with an overall 5-year survival rate reported less than 5% due to late diagnosis.
  • Advent of ultrasound scanning may help in detecting gallbladder polyps and an early gallbladder cancer.
  • Excellent 5-year survival (up to 100%) has been reported for Stage Ia disease and the survival has significantly improved for Stage Ib, II, and III if appropriate re-operation is carried out soon after the incidental detection of gallbladder cancer.
  • Laparoscopic cholecystectomy (LC) is contraindicated in the presence of gallbladder cancer.
  • It is recommended to excise all laparoscopic port sites, at the time of re-operation.
  • Re-operation for Stage II gallbladder cancer is associated with a 90-100% 3-year survival rate.
  • Patients with Stage III and IV tumors also benefit from an extended cholecystectomy.
  • It is advantageous to perform the appropriate extent of surgery for gallbladder cancer at the initial operation.
  • Heightened awareness of the presence of cancer and the knowledge of appropriate management are important.
  • For patients whose cancer is an incidental finding on pathologic review, re-resection is indicated for all disease except Stage Ia.
  • Radiotherapy and chemotherapy have not been found effective as an adjuvant or palliative therapy in gallbladder cancer.
  • [MeSH-major] Cholecystectomy, Laparoscopic. Gallbladder Diseases / surgery. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / surgery
  • [MeSH-minor] Cholecystectomy. Gallbladder / pathology. Gallbladder / ultrasonography. Hepatectomy. Humans. Incidental Findings. Laparoscopy. Lymph Node Excision. Neoplasm Staging. Polyps / epidemiology. Polyps / ultrasonography. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16724357.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


17. Fan YZ, Fu JY, Zhao ZM, Chen CQ: Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells. Hepatobiliary Pancreat Dis Int; 2004 Nov;3(4):603-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells.
  • BACKGROUND: Gallbladder carcinoma is a highly lethal and aggressive disease with early metastasis, strong invasion and poor prognosis.
  • Most patients with this disease are at the advanced and un-resectable stage and should be considered for palliative treatment such as chemotherapy and radiotherapy.
  • Unfortunately, reports of chemotherapy and radiotherapy for gallbladder carcinoma are disappointing.
  • We investigated the influence of norcantharidin (NCTD) on proliferation, proliferation-related gene proteins PCNA and Ki-67 of human gallbladder carcinoma GBC-SD cells in vitro.
  • METHODS: GBC-SD cell lines of human gallbladder carcinoma were cultured by the cell culture technique.
  • The streptavidin-biotin complex method was used to determine the expressions of proliferation-related gene proteins PCNA and Ki-67 of human gallbladder carcinoma GBC-SD cells.
  • RESULTS: NCTD inhibited the growth and proliferation of GBC-SD cells from 10 mg/L or after 6 hours in a dose-and time-dependent manner, with the IC50 value of 56.18 microg/ml at 48 hours.
  • After treatment with NCTD, the expression of PCNA (0.932+/-0.031 vs. 0.318+/-0.023, P<0.001) and Ki-67 (0.964+/-0.092 vs. 0.297+/-0.018, P<0.001) proteins were decreased significantly.
  • CONCLUSION: NCTD inhibits the proliferation of human gallbladder carcinoma GBC-SD cells in vitro and the expression of their proliferation-related gene proteins PCNA and Ki-67.
  • [MeSH-major] Bicyclo Compounds, Heterocyclic / pharmacology. Carcinoma / metabolism. Carcinoma / pathology. Gallbladder Neoplasms / metabolism. Gallbladder Neoplasms / pathology. Ki-67 Antigen / metabolism. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Immunohistochemistry / methods. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567755.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bicyclo Compounds, Heterocyclic; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 5442-12-6 / norcantharidin
  •  go-up   go-down


18. Wang BL, Zhai HY, Chen BY, Zhai SP, Yang HY, Chen XP, Zhao WT, Meng L: Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis Int; 2004 May;3(2):296-9
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relationship between MDR1 gene and gallbladder cancer.
  • BACKGROUND: The most common mechanisms of multidrug resistance (MDR) in cancer cells is the expression of an energy-dependent exfflux pump.
  • It is a major therapeutic problem in cancer chemotherapy.
  • The aim of this study is to study the expression of MDR1 gene encoding P-gp and MDRl mRNA in primary gallbladder carcinoma, and analyze its clinical significance.
  • METHODS: Immunohistochemistry (IHC) S-P method and in situ polymerase chain reaction (ISPCR) were used to detect the expression of P-gp and MDR1 mRNA in 53 cases of untreated primary gallbladder carcinoma and 12 cases of cholecystitis (archival paraffin-embedded tissues).
  • The positive expression rate of P-gp and MDR1mRNA were 69.44%, 83.33% and 41.18%, 47.06% respectively in tissues in stage of Nevin I-III against Nevin IV, V (P<0.05).
  • In well, moderately differentiated gallbladder carcinoma tissues, their expressions were 79.49%, 69.23% against 50.00%, 35.71% in low, undifferentiated tissues (P<0.05).
  • CONCLUSIONS: MDR to gallbladder carcinoma is closely related to the intrinsic MDR and it provides an important evidence to reverse the MDR by detection of the MDR1 gene.
  • Meanwhile, MDR1 gene expression in gallbladder carcinoma is correlated with some biological characteristics, takes part in the carcinogenesis of gallbladder tissues, and acts as a valuable biomarker of prognosis.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma / genetics. Gallbladder Neoplasms / genetics. Genes, MDR / genetics. P-Glycoprotein / genetics
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15138130.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 0 / RNA, Messenger
  •  go-up   go-down


19. Park HS, Lim JY, Yoon DS, Park JS, Lee DK, Lee SJ, Choi HJ, Song SY, Lee WJ, Cho JY: Outcome of adjuvant therapy for gallbladder cancer. Oncology; 2010;79(3-4):168-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adjuvant therapy for gallbladder cancer.
  • OBJECTIVES: The aim of this study was to evaluate the outcome of adjuvant therapy on the overall survival (OS) and disease-free survival (DFS) after curative resection (RO) of patients with TNM stage II gallbladder (GB) cancer.
  • Among 61 stage II GB cancer patients, 43 received adjuvant therapy, while 18 others received surgery alone.
  • RESULTS: OS was not significantly different among the adjuvant therapies (p = 0.180), but DFS was (p = 0.033).
  • The 3-year OS and DFS from surgery alone, adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant concurrent chemo-radiotherapy were 64, 78, 36 and 36%, and 56, 69, 14 and 47%, respectively.
  • Overall, the chemotherapy group had a better prognosis, although there were no significant differences.
  • CONCLUSIONS: The data from this study do not provide evidence that adjuvant therapy is an effective treatment option for curative resected GB cancer.
  • A large randomized controlled study is necessary to confirm the efficacy of adjuvant therapy.
  • Newer adjuvant studies should be focused on gemcitabine-based chemotherapy or chemo-radiotherapy with molecular-based target agents.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / therapy. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21212704.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Tewari M, Kumar V, Mishra RR, Kumar M, Shukla HS: Is there a role for cholecystectomy in gallbladder carcinoma discovered to be unresectable for cure at laparotomy? World J Surg; 2008 Dec;32(12):2683-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for cholecystectomy in gallbladder carcinoma discovered to be unresectable for cure at laparotomy?
  • BACKGROUND: Palliative operative resection in patients with locally advanced cancer of the gallbladder (GBC) found not to be amenable to radical resection for cure at exploration has received little attention.
  • Of these, 30 patients (group I) with GBC (T(3-4),N(0-1),M(0)) treated with cholecystectomy +/- biliary bypass were selected and compared with equal number of controls matched for age (+/-5 years), sex, histopathology, stage, residence, and postoperative chemotherapy who underwent biopsy +/- biliary bypass only (group II) followed by chemotherapy during the same period.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cholecystectomy. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / surgery. Palliative Care
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. India. Kaplan-Meier Estimate. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2008 Dec;32(12):2688-9 [18850247.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Apr;8(2):161-7 [16533480.001]
  • [Cites] Kongressbd Dtsch Ges Chir Kongr. 2002;119:79-81 [12704874.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1547-51 [10430292.001]
  • [Cites] Eur J Surg. 1993 Aug;159(8):415-20 [8218552.001]
  • [Cites] Hepatogastroenterology. 1991 Apr;38(2):170-5 [1649788.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):699-704 [16724351.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2138-43 [10521956.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1145-9 [8630890.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):108-10 [7906181.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Nov;4(4):589-92 [16286269.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):418-22 [10759735.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):183-90 [15036194.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):604-6 [16724359.001]
  • [Cites] Ann Surg. 1982 May;195(5):624-31 [7073360.001]
  • [Cites] Br J Surg. 1999 May;86(5):622-7 [10361182.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):670-81 [16724356.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):650-64 [16724342.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):705-8 [16724358.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):174-7 [12714891.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Feb;20(2):309-14 [15683437.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Nov;2(4):581-6 [14627524.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Aug;16(8):848-54 [11555095.001]
  • [Cites] Am J Gastroenterol. 1995 Dec;90(12):2195-200 [8540515.001]
  • (PMID = 18836852.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kayahara M, Nagakawa T: Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients. Cancer; 2007 Aug 1;110(3):572-80
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients.
  • BACKGROUND: Gallbladder cancer is the most common cancer of the biliary tract and has a particularly high incidence in Chile, Japan, and northern India.
  • Many Japanese surgeons have reported that aggressive surgery improves the outcome of patients with gallbladder cancer.
  • The objective of this study was to determine whether there were any changes over time in the incidence, therapeutic approach, stage at diagnosis, or prognosis of gallbladder cancer in an unselected, community-based series of patients in Japan.
  • METHODS: In total, 4,774 patients with gallbladder cancer were analyzed between 1988 and 1997 based on data from the Biliary Tract Cancer Registration Committee of the Japanese Society of Biliary Surgery.
  • RESULTS: Survival was related closely to surgical stage, with 5-year survival rates of 77% for patients with stage I disease, 60% for patients with stage II disease, 29% for patients with stage III disease, 12% for patients with stage IVA disease, and 3% for patients with stage IVB disease.
  • Stratifying patients by stage according to the Japanese Society of Biliary Surgery classification showed that women maintained a survival advantage over men among patients with stage I and II disease.
  • Adjuvant chemotherapy did not provide a survival benefit.
  • CONCLUSIONS: For this study, the authors evaluated the gallbladder cancer trends in Japan.
  • The Classification of Biliary Tract Carcinoma proposed by the Japanese Society of Biliary Surgery reflected the prognosis of patients with gallbladder cancer.
  • The data did not support any advantage for aggressive surgical resection and adjuvant chemotherapy.
  • Further analysis of operative procedures will be necessary to determine conclusively whether there is any survival advantage from aggressive surgery in patients with advanced gallbladder cancer.
  • [MeSH-major] Gallbladder Neoplasms / epidemiology. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Japan / epidemiology. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17594719.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J: Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res; 2005 Aug 1;11(15):5572-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
  • Biliary tract cancer (BTC) is the second most common primary hepatobiliary cancer after hepatocellular cancer.
  • At the time of diagnosis, most BTC are at an advanced stage and are unresectable.
  • There is presently no effective curative treatment of the advanced disease nor is there any effective clinical therapy that will prevent the development of BTC.
  • All of these factors render gallbladder cancer nearly incurable with a poor survival rate.
  • The aim of our study was to provide a better understanding of the mechanisms involved in the development of gallbladder carcinoma as the advancement of more effective treatment options would significantly improve prognosis.
  • In the present study, we examined the effect of gefitinib, a selective epidermal growth factor receptor/tyrosine kinase inhibitor (EGFR/TKI), on the development of gallbladder carcinoma in BK5.erbB2 mice.
  • Animals were treated with either 400 ppm gefitinib or 200 ppm GW2974 as a supplement in the diet using either a chemopreventive or therapeutic protocol.
  • The results show that both compounds were potent chemopreventive and therapeutic agents in this mouse model of human BTC.
  • The results also suggest that activation of the EGFR plays an important role in development of BTC in this model and that targeting both the EGFR and erbB2 may be an effective strategy for treatment of this disease.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Enzyme Inhibitors / pharmacology. Gallbladder Neoplasms / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Blotting, Western. Body Weight. Cell Line, Tumor. Disease Models, Animal. Gallbladder / metabolism. Humans. In Situ Nick-End Labeling. MAP Kinase Signaling System. Mice. Mice, Transgenic. Microscopy, Fluorescence. Neoplasms, Experimental. Phosphorylation. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Tolonium Chloride / pharmacology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061875.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NIEHS NIH HHS / ES / ES07784; United States / NCI NIH HHS / CA / R01 CA099526
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / GW2974; 0 / Quinazolines; 15XUH0X66N / Tolonium Chloride; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; S65743JHBS / gefitinib
  •  go-up   go-down


23. Kaman L, Behera A, Singh G, Nedounsejiane M: Radical surgery for incidental cancer gallbladder after laparoscopic cholecystectomy. Trop Gastroenterol; 2009 Oct-Dec;30(4):233-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical surgery for incidental cancer gallbladder after laparoscopic cholecystectomy.
  • OBJECTIVE: To report our experience in the management of incidentally detected carcinoma gall bladder and establishment of a treatment protocol.
  • METHOD: Retrospective review of 7 patients with incidentally detected carcinoma gall bladder during and after laparoscopic cholecystectomy for presumed benign disease.
  • Clinical and histopathological data, treatment and long term outcome of all seven patients were reviewed.
  • Postoperatively, 2 patients developed fever and 1 patient had minimal altered blood in the nasogastric tube aspirate.
  • All 7 patients had disease of pathological stage II and beyond.
  • All patients received adjuvant chemotherapy.
  • CONCLUSION: Re-exploration and aggressive resection with adjuvant chemotherapy for incidental carcinoma of the gallbladder is safe and offers hope for long term survival.
  • [MeSH-major] Cholecystectomy, Laparoscopic. Gallbladder Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Incidental Findings. Lymph Node Excision. Male. Middle Aged. Postoperative Complications. Reoperation. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426289.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


24. Ortiz J, Reich D, Joon HB, Martinez O, Manzarbeitia C: Six year disease free survival after liver transplantation in a patient with T3 gallbladder carcinoma: case presentation and review of the literature. World J Surg Oncol; 2006;4:45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Six year disease free survival after liver transplantation in a patient with T3 gallbladder carcinoma: case presentation and review of the literature.
  • BACKGROUND: The incidence of gallbladder carcinoma in cirrhotics is unknown.
  • CASE PRESENTATION: A sixty year old with primary sclerosing cholangitis, cirrhosis, and gallbladder polyps underwent liver transplantation.
  • A polypoid lesion measuring 1.5 x 0.5 cm was found on the fundus of the gallbladder.
  • Histological examination revealed moderately differentiated adenocarcinoma with full thickness penetration of the gallbladder encroaching liver parenchyma.
  • No chemotherapy was given.
  • He is currently six years post procedure and free of disease.
  • CONCLUSION: "Incidentally" discovered stage IIA gallbladder carcinoma may not negatively affect long term survival after liver transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2004 Feb;28(2):160-5 [14708053.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):83-9; discussion 89 [14746839.001]
  • [Cites] Clin Liver Dis. 1998 May;2(2):283-301, viii [15560033.001]
  • [Cites] World J Surg. 2004 Jan;28(1):47-9 [14639492.001]
  • [Cites] Transplant Proc. 2003 Nov;35(7):2431-4 [14611979.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(3):233-8 [14605981.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):167-76 [12623362.001]
  • [Cites] Am J Gastroenterol. 2002 May;97(5):1138-42 [12014717.001]
  • [Cites] Can J Gastroenterol. 2002 Feb;16(2):87-93 [11875592.001]
  • [Cites] J Am Coll Surg. 2001 May;192(5):600-7 [11333097.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Apr;11(2):88-91 [11330390.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):295-314; questionnaire, 549-55 [11259693.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):65-70 [11248179.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):191-218 [11218916.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):924-33 [7877651.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):149-52 [9934746.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):412-23 [9527065.001]
  • [Cites] Am J Surg. 1998 Feb;175(2):118-22 [9515527.001]
  • [Cites] Hepatology. 1998 Feb;27(2):311-6 [9462625.001]
  • [Cites] J Hepatol. 1997 Sep;27(3):512-6 [9314129.001]
  • [Cites] Ann Surg. 1997 May;225(5):472-81; discussion 481-3 [9193175.001]
  • [Cites] HPB Surg. 1994;8(2):147-9 [7880774.001]
  • (PMID = 16842623.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1540419
  •  go-up   go-down


25. Malik IA: Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases. J Gastroenterol Hepatol; 2003 Aug;18(8):950-3
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases.
  • BACKGROUND AND AIMS: Gallbladder cancer is common in Pakistan and has an extremely poor prognosis.
  • Treatment is primarily surgical.
  • Chemotherapy is frequently used in patients with advanced disease.
  • This study was performed to evaluate and compare the clinicopathological features and management of gallbladder cancer in Pakistani patients, with particular emphasis on factors that influence survival.
  • METHODS: Two hundred and thirty-three patients with histologically proven gallbladder cancer were studied.
  • Information was prospectively collected on demographic features, clinical and laboratory findings at the time of presentation, influence of therapy, and survival.
  • The majority (69%) had a history of symptomatic gallbladder disease.
  • Most had abnormal hepatic function tests and 58% had elevated carcinoma embryonic antigen levels.
  • Stage (P < 0.001), jaundice (P = 0.01) and palpable mass (P = 0.02) were statistically significant variables.
  • However, on multivariate analysis, tumor node metastases (TNM) stage was the only factor influencing survival.
  • Median survival of the patients was 44 months for patients with stage I disease, 23 months for stage II, 17 months for stage III and 6 months for stage IV.
  • Most patients presented at an advanced stage of disease and had an extremely poor prognosis.
  • Systemic therapy did not provide any survival benefit.
  • The TNM stage remains the most important factor influencing survival.
  • [MeSH-major] Adenocarcinoma / therapy. Gallbladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859725.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


26. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM: A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol; 2007 Nov;14(11):3202-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
  • AIM: To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and capecitabine in patients with advanced biliary cancer.
  • All patients completed the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Pancreatic Cancer Module (EORTC QLQ-C30-PAN 26) questionnaire on day 1 of each cycle.
  • The two-stage design required 17 patients to evaluate the confirmed response at nine weeks.
  • Four out of seven patients with CBR had no decline in QOL with chemotherapy.
  • There were no treatment-related deaths.
  • CONCLUSIONS: Gemcitabine and capecitabine at this dose and schedule are well tolerated and effective and may offer clinical benefit and maintain QOL in patients with advanced biliary cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705089.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Yildirim Y, Akcali Z, Bilezikci B, Ozyilkan O: Primary squamous cell carcinoma of the stomach: a case report. Tumori; 2005 Sep-Oct;91(5):440-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the stomach: a case report.
  • Squamous cell carcinoma (SCC) originating from the stomach is a relatively rare entity.
  • Due to the advanced stage at the time of diagnosis in most of these cases, the prognosis is generally poor.
  • In the case presented here, dissemination of the tumor to the transverse colon, gallbladder and omentum was present at diagnosis.
  • Despite the tumor's advanced stage, complete remission was achieved after six courses of adjuvant chemotherapy with 5-flourouracil and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Treatment Outcome


28. Endo I, Masunari H, Sugita M, Morioka D, Tanaka K, Togo S, Sekido H, Yoshida T, Shimada H: [Indications for combined resection and reconstruction of the hepatic artery in biliary tract carcinoma]. Nihon Geka Gakkai Zasshi; 2001 Nov;102(11):820-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indications for combined resection and reconstruction of the hepatic artery in biliary tract carcinoma].
  • More than 10 years have passed since hepatic artery resection was first performed for the treatment of biliary tract cancer.
  • The safety of this procedure has been established with the introduction of the microsurgery technique.
  • However, the benefits of and indications for this treatment have not yet been clarified.
  • Twenty-three patients underwent vascular resection (portal vein in 7, portal vein + hepatic artery in 9, hepatic artery in 7) among 114 resected patients with biliary tract cancer in our institution.
  • The curative resection rate was 88.9% in hilar bile duct cancer.
  • Cumulative 5-year survival rates of vascular resection patients with hilar bile duct cancer, lower bile duct cancer, gallbladder cancer, and cholangiocarcinoma were 14.8%, 25%, 0%, and 0%, respectively.
  • On the other hand, the rates were 38.9%, 0%, 0%, and 0%, in the stage III + IV patients who did not undergo vascular resection.
  • The longest survival period among patients with hilar bile duct cancer and lower bile duct cancer was 85 months and 65 months, respectively, whereas it was 15 months in gallbladder cancer and 20 months in cholangiocarcinoma patients.
  • No hilar bile duct cancer patient who survived for more than 3 years had lymph node metastasis.
  • The longest surviving cholangiocarcinoma patient has received adjuvant chemotherapy consisting of 5-fluorouracil and cisplatin.
  • It is concluded that patients with hilar bile duct cancer are good candidates for vascular resection.
  • Adjuvant chemotherapy should be administered to gallbladder cancer and cholangiocarcinoma patients, because vascular resection alone does not result in prolongation of life in these patients.
  • [MeSH-minor] Aged. Anastomosis, Surgical / methods. Chemotherapy, Adjuvant. Cholangiocarcinoma / mortality. Cholangiocarcinoma / surgery. Female. Gallbladder Neoplasms / mortality. Gallbladder Neoplasms / surgery. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11729649.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. van der Hoeven J, Busch O, Bijnen C, Gouma D, van Gulik T: [Diagnosis and treatment of carcinoma of the gall bladder]. Ned Tijdschr Geneeskd; 2010;154:A355
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of carcinoma of the gall bladder].
  • Over the past decade considerable progress has been made in several fields relating to the diagnosis and treatment of gall bladder cancer.
  • This literature search evaluates if these recent advances have led to improved diagnosis, treatment and survival of patients with gall bladder carcinoma.
  • The increase in the number of cholecystectomies being carried out has resulted in more carcinomas being discovered incidentally, and at an early and treatable stage.
  • Current radiotherapy and chemotherapy in adjuvant and neoadjuvant settings have not shown any survival benefit.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cholecystectomy. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20356434.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 28
  •  go-up   go-down


30. André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer; 2008 Sep 16;99(6):862-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
  • Advanced biliary tract carcinomas (BTCs) are often diagnosed at an advanced/metastatic stage and have a poor prognosis.
  • This international phase II study evaluated the efficacy and safety of GEMOX as first-line therapy in patients with advanced BTCs.
  • The objective response rate was 20.5% in patients with non-gallbladder cancers (9/44 patients) and 4.3% in patients with gallbladder cancers (1/23).
  • Grade 3/4 toxicities included thrombocytopenia (14.9% of patients), alanine aminotransferase elevation (13.4%), anaemia (10.4%), neutropenia (11.9%) and pain (1 1.9%).
  • In this study, GEMOX demonstrated activity in non-gallbladder carcinoma, but poor activity in gallbladder carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Female. Humans. International Agencies. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Oncology. 2006;70(4):280-4 [17047399.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):47-52 [17364190.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] BMC Cancer. 2002 May 3;2:10 [11991810.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):117-23 [10412945.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003 [16724985.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii68-72 [16760298.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64 [11760569.001]
  • (PMID = 19238628.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; gemcitabine-oxaliplatin regimen
  • [Other-IDs] NLM/ PMC2538748
  •  go-up   go-down


31. Ogo Y, Nio Y, Yano S, Toga T, Koike M, Hashimoto K, Itakura M, Maruyama R: Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Res; 2006 Jan-Feb;26(1B):763-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma.
  • The clinicopathological significance of HER-1- and HER-2-overexpressions (OE) (HercepTest score 2+ or 3+) in biliary cancer and their relationship to the efficacy of adjuvant chemotherapy (ACT) were assessed.
  • In 72 biliary cancer (28 gallbladder and 44 bile duct cancer), HER-1 and HER-2 were stained immunohistochemically in formalin-fixed, paraffin-embedded specimens.
  • Out of the 72 cancer, OE was observed in 31 specimens (43%) for HER-1 and 47 (65%) for HER-2.
  • HER-2-OE was inversely correlated with the clinical stage (p=0.0482).
  • HER-1-OE was correlated with distant metastasis (p=0.0263), but not with the clinical stage.
  • In conclusion, neither HER-1-OE or HER-2-OE were prognostic factors of the biliary cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739351.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


32. Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist; 2008 Apr;13(4):415-23
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for biliary tract cancers.
  • Biliary tract cancers (BTCs) are invasive carcinomas that arise from the epithelial lining of the gallbladder and bile ducts.
  • These include intrahepatic, perihilar, and distal biliary tree cancers as well as carcinoma arising from the gallbladder.
  • Complete surgical resection offers the only chance for cure; however, only 10% of patients present with early-stage disease and are considered surgical candidates.
  • Among those patients who do undergo "curative" resection, recurrence rates are high; thus, for the majority of BTC patients, systemic chemotherapy is the mainstay of their treatment plan.
  • Patients with unresectable or metastatic BTC have a poor prognosis, with a median overall survival time of <1 year.
  • Despite a paucity of randomized phase III data, a consensus on first-line systemic therapy is emerging.
  • In this review, we discuss the clinical experience with systemic treatment of BTC, focusing on the rationale for a first-line regimen as well as future directions in the field.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Cholangiocarcinoma / drug therapy
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Humans. Randomized Controlled Trials as Topic. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448556.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 70
  •  go-up   go-down


33. Abou-Alfa GK, Rowinsky EK, Patt YZ, Schwartz GK, Kelsen DP, Sharma S, Siegel E, Becerra CR, Eckhardt SG, Feit K, De Jager R, O'Reilly EM: A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol; 2005 Aug;28(4):334-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma.
  • METHODS: Patients with 0 to 1 prior chemotherapy regimens, adequate major organ function, and metastatic disease were eligible.
  • A Simon optimal 2-stage design was employed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Camptothecin / analogs & derivatives. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Drug Administration Schedule. Female. Half-Life. Humans. Male. Middle Aged. Survival Rate. Topoisomerase I Inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062073.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Topoisomerase I Inhibitors; 0 / exatecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


34. Eckel F, Schmid RM: Emerging drugs for biliary cancer. Expert Opin Emerg Drugs; 2007 Nov;12(4):571-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for biliary cancer.
  • Biliary cancer comprise carcinoma of the gallbladder as well as the intrahepatic, hilar and extrahepatic bile ducts.
  • It is often diagnosed at an advanced stage when potentially curative resection is not feasible.
  • Due to the lack of randomised Phase III studies, there is no standard regimen for chemotherapy in biliary cancer.
  • Recent investigations into the underlying molecular mechanisms involved in biliary carcinogenesis and tumour growth have contributed greatly to our understanding of biliary cancer.
  • Through a better understanding of these mechanisms, improved and more specific diagnostic, therapeutic and preventive strategies may be developed.
  • Although fluoropyrimidines and gemcitabine remain the backbone of routine chemotherapy in advanced disease, new agents such as epidermal growth factor receptor blockers and angiogenesis inhibitors may hold promise for improving the outcome for patients with biliary cancer.
  • [MeSH-major] Antineoplastic Agents. Biliary Tract Neoplasms / drug therapy. Drug Design
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Industry. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979600.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 81
  •  go-up   go-down


35. Selvakumar P, Pasha MK, Ashakumary L, Dimmock JR, Sharma RK: Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review). Int J Mol Med; 2002 Oct;10(4):493-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review).
  • Colorectal cancer is the second leading cause of malignant death, and better preventive strategies are needed.
  • The treatment of colonic cancer remains difficult because of the lack of effective chemotherapeutic agents; therefore it is important to continue to search for cellular functions that can be disrupted by chemotherapeutic drugs resulting in the inhibition of the development and progression of cancer.
  • This process is involved in the pathogenesis of cancer.
  • We have reported for the first time in rats treated with azoxymethane that NMT activity was higher in colonic epithelial neoplasms than in normal colonic tissue and that an increase in NMT activity appeared at an early stage in colonic carcinogenesis.
  • Increased NMT activity was also confirmed in human colonic tumors compared to normal tissue.
  • In addition, gallbladder carcinoma showed moderate to strong cytoplasmic positivity for NMT with increased intensity in the invasive component whereas the normal gallbladder mucosa showed weak to negative cytoplasmic staining for this enzyme.
  • It is conceivable therefore that NMT can be used as a potential marker for the early detection of cancer.
  • Of particular note is the very recent discovery of cytotoxic compounds in the laboratories of the authors which inhibit NMT and may offer a novel approach for the evolution of candidate antineoplastic agents which display greater potencies towards neoplasms than the corresponding normal tissues.
  • [MeSH-major] Acyltransferases / metabolism. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Biomarkers. Carcinoma / metabolism. Gallbladder Neoplasms / metabolism. Humans. Rats

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12239600.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.3.- / Acyltransferases; EC 2.3.1.97 / glycylpeptide N-tetradecanoyltransferase
  • [Number-of-references] 70
  •  go-up   go-down


36. Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O: Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):842-7
Genetic Alliance. consumer health - Primary sclerosing cholangitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At entry, 11 patients had a diagnosis of hepatobiliary or colon malignancy (cholangiocarcinoma: n = 5, hepatocellular carcinoma: n = 2, gallbladder carcinoma: n = 1 and colorectal cancer: n = 4).
  • RESULTS: During follow-up [3.9 (0.1-7.2) years], colorectal cancer was diagnosed in four patients and biliary carcinoma in two (incidences: 0.76 and 0.38 for 100 patient-years, respectively).
  • Main causes of death (n = 10) were cancer (n = 5, including three colorectal cancers and two cholangiocarcinoma) or liver failure (n = 4).
  • Indications for transplantation (n = 25) were end-stage liver disease (n = 16), biliary cancer (known or suspected) (n = 5), recurrent acute cholangitis (n = 3) or pruritus (n = 1).
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / drug effects. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / drug therapy. Cohort Studies. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Female. France / epidemiology. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / drug therapy. Humans. Incidence. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Transplantation. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome. Ursodeoxycholic Acid / therapeutic use. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779305.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


37. Lepistö A, Kivistö S, Kivisaari L, Arola J, Järvinen HJ: Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolecetomy for ulcerative colitis. Int J Colorectal Dis; 2009 Oct;24(10):1169-74
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One carcinoma of the gallbladder was found in MRI.
  • Compared to stage in peroperative biopsies taken at proctocolectomy, PSC stage increased in four (13%) patients, decreased in 15 (50%), and remained unchanged in 11 (37%).
  • Of the 68, six patients have, to date, developed cholangiocarcinoma.
  • CONCLUSIONS: Progression of PSC in patients with minor ductal changes at the time of restorative proctocolectomy is unlikely.
  • [MeSH-minor] Anastomosis, Surgical. Biopsy. Cholangiocarcinoma / complications. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Colonic Pouches. Female. Humans. Liver / pathology. Liver Function Tests. Liver Transplantation. Magnetic Resonance Imaging. Male. Treatment Outcome. Ursodeoxycholic Acid / therapeutic use

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S30-4 [11084082.001]
  • [Cites] Curr Opin Gastroenterol. 2004 May;20(3):275-80 [15703653.001]
  • [Cites] Gastroenterology. 1987 Jun;92(6):1869-75 [3569762.001]
  • [Cites] J Hepatol. 2002 Mar;36(3):321-7 [11867174.001]
  • [Cites] Pediatr Dev Pathol. 2007 Sep-Oct;10(5):383-90 [17929991.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:89-93 [10436794.001]
  • [Cites] Hepatology. 1981 Nov-Dec;1(6):632-40 [7308996.001]
  • [Cites] Hepatogastroenterology. 1995 Feb;42(1):68-72 [7782040.001]
  • [Cites] Scand J Gastroenterol. 1987 Aug;22(6):655-64 [3659828.001]
  • [Cites] Int J Cancer. 1996 May 3;66(3):326-31 [8621252.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1893-901 [1451982.001]
  • [Cites] J Hepatol. 2007 Nov;47(5):677-83 [17640760.001]
  • [Cites] Br J Surg. 2008 Jul;95(7):882-6 [18496886.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1464-72 [16285948.001]
  • [Cites] Semin Liver Dis. 1991 Feb;11(1):31-9 [2047887.001]
  • [Cites] J Hepatol. 2004 May;40(5):815-22 [15094230.001]
  • [Cites] Scand J Gastroenterol. 1999 Jul;34(7):714-22 [10466884.001]
  • [Cites] Inflamm Bowel Dis. 2008 Jun;14(6):775-9 [18253951.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):1155-8 [12809842.001]
  • [Cites] Gut. 1980 Oct;21(10 ):870-7 [7439807.001]
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):523-6 [15056096.001]
  • [Cites] Liver. 2001 Feb;21(1):50-5 [11169073.001]
  • (PMID = 19636573.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down






Advertisement